drugset / Trial / NCT05806749
Immunological Tolerance in Patients With Mismatched Kidney Transplants
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated living donor kidney and hematopoietic stem cell transplantation.
Timeline
- Start
- 2023-07-07
- Primary completion
- 2028-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belumosudil | Small molecule | 200 mg | Oral |
| Background | Donor CD3+ | Unknown | 1e+08 cells/kg | — |
| Background | Donor CD34+ | Cell therapy | 1e+07 cells/kg | — |